Novo Nordisk Shares Plunge as 2026 Outlook Darkens Amid Lilly Rivalry and U.S. Pricing Pressures
Novo Nordisk forecasts a significant drop in sales and profits for 2026, citing intense competition from Eli Lilly and U.S. government pricing constraints, sending its stock tumbling and wiping billions from its market value.